CorMedix: A Fair-Priced Biotech Company With A Bright Future

Group 1 - CorMedix Inc. is a growth company benefiting from the launch of its new drug, DefenCath, which has received FDA approval in 2023 [1] - DefenCath specifically addresses catheter-related bloodstream infections in patients undergoing hemodialysis [1] Group 2 - The company is positioned in a niche market with significant potential for growth due to the specific medical need it addresses [1]